Department of Urology, Emory University School of Medicine, 1365 Clifton Rd, NE, Building B, Atlanta, GA 30322, USA.
J Clin Oncol. 2010 Feb 20;28(6):1069-74. doi: 10.1200/JCO.2009.26.2469. Epub 2010 Jan 25.
PURPOSE Men diagnosed with prostate cancer have multiple options available for treatment. Previous reports have indicated a trend of differing modalities of treatment chosen by African American and white men. We investigated the role of ethnicity in primary treatment choice and how this affected overall and cancer-specific mortality. METHODS By utilizing data abstracted from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), patients were compared by ethnicity, primary treatment, number of comorbidities, risk level according to modified D'Amico criteria, age, highest educational level attained, type of insurance, treatment facility, and perception of general health. Multinomial logistic regression analysis was performed to determine the effect of the tested variables on primary treatment and mortality. Results African American men were more likely to receive nonsurgical therapy than white men with equivalent disease characteristics. Whites were 48% less likely than African Americans to receive androgen deprivation therapy (ADT) compared with surgery (P = .02) and were 25% less likely than African Americans to receive radiation therapy compared with surgery (P = .08). Whites with low-risk disease were 71% less likely to receive ADT than African American men with similar disease (P = .01). Adjusted overall and prostate cancer-specific mortality were not significantly different between whites and African Americans (hazard ratios, 0.73 and 0.37, respectively). Risk level, type of treatment, and type of insurance had the strongest effects on risk of mortality. CONCLUSION There is a statistically significant difference in primary treatment for prostate cancer between African American and white men with similar risk profiles. Additional research on the influence of patient/physician education and perception and the role that socioeconomic factors play in mortality from prostate cancer may be areas of focus for public health initiatives.
患有前列腺癌的男性有多种治疗选择。先前的报告表明,非裔美国男性和白人男性选择的治疗方式存在差异趋势。我们调查了种族在主要治疗选择中的作用,以及这如何影响总体和癌症特异性死亡率。
通过利用从前列腺癌战略泌尿科研究努力(CaPSURE)中提取的数据,根据种族、主要治疗方法、合并症数量、根据改良 D'Amico 标准确定的风险水平、年龄、最高教育程度、保险类型、治疗设施以及对总体健康状况的看法对患者进行比较。进行多项逻辑回归分析,以确定测试变量对主要治疗和死亡率的影响。
具有同等疾病特征的非裔美国男性比白人男性更有可能接受非手术治疗。与手术相比,白人接受雄激素剥夺治疗(ADT)的可能性比非裔美国人低 48%(P =.02),与手术相比,白人接受放射治疗的可能性比非裔美国人低 25%(P =.08)。低危疾病的白人接受 ADT 的可能性比非裔美国人低 71%(P =.01)。调整后的总体和前列腺癌特异性死亡率在白人和非裔美国人之间没有显著差异(风险比分别为 0.73 和 0.37)。风险水平、治疗类型和保险类型对死亡率风险的影响最大。
在具有相似风险特征的非裔美国男性和白人男性中,前列腺癌的主要治疗方法存在统计学上的显著差异。关于患者/医生教育和认知的影响以及社会经济因素在前列腺癌死亡率中的作用的进一步研究可能是公共卫生倡议的重点领域。